Recent advancements in gene supplementation therapy are expanding the options for the
treatment of neurological disorders. Among the available delivery vehicles, adeno …

Epilepsy is a common brain disorder, characterized by spontaneous recurrent seizures, with
associated neuropsychiatric and cognitive comorbidities and increased mortality. Although …

In the last 30 years, over 20 new anti-seizure medicines (ASMs) have been introduced into
the market for the treatment of epilepsy using well-established preclinical seizure and …

Schizophrenia (SCZ) is a highly heterogeneous disorder with diverse clinical manifestations
and macro-and microscale biological variations, usually observed at dissociable levels …

Epilepsy affects 1% of the general population and 30% of patients are resistant to
antiepileptic drugs. Although optogenetics is an efficient antiepileptic strategy, the difficulty of …

Epilepsy is a prevalent disorder involving neuronal network hyperexcitability, yet existing
therapeutic strategies often fail to provide optimal patient outcomes. Chemogenetic …

The advent of optogenetic tools has had a profound impact on modern neuroscience
research, revolutionizing our understanding of the brain. These tools offer a remarkable …

The pharmacological treatment of epilepsy is purely symptomatic. Despite many decades of
intensive research, causal treatment of this common neurologic disorder is still unavailable …

Inborn errors of neurotransmitter (NT) metabolism are a group of rare, heterogenous
diseases with predominant neurological features, such as movement disorders, autonomic …

Developmental and epileptic encephalopathies (DEEs) are severe seizure disorders with
inadequate treatment options. Gain-or loss-of-function mutations of neuronal ion channel …